Welcome to our dedicated page for Adia Med news (Ticker: ADIA), a resource for investors and traders seeking the latest updates and insights on Adia Med stock.
ADIA Nutrition Inc. (ADIA) reports developments tied to its regenerative medicine, stem cell therapy, and biologic products business. The company operates through Adia Med clinics, which offer treatments such as PRP, AHSCT, orthopedic care, pain management, and wound repair, and through Adia Labs, which develops and sells biologic products including AdiaVita and AdiaLink.
Company news commonly covers clinical and regulatory activity involving AdiaVita, including study programs in chronic kidney disease, autism spectrum disorder, and chronic lower back pain. Updates also address operating results, product sales and medical-service revenue, capital-structure disclosures, governance matters, and the company's transition from a supplement-oriented business toward regenerative healthcare.
ADIA Nutrition Inc. (OTC Pink: ADIA) has announced two significant developments in its distribution strategy. Firstly, the company has registered with RangeMe, a product discovery platform that connects them with over 15,000 buyers from major retailers like Walmart, CVS, and 7-11. This move allows ADIA to showcase its innovative product, Biolete, a protein coffee with mushrooms designed for health-conscious consumers.
Secondly, ADIA has submitted an application for Walmart's Open Call event in September, where suppliers can pitch their products directly to Walmart buyers. CEO Larry Powalisz expressed excitement about these opportunities, stating they represent significant steps in expanding distribution channels and potentially securing shelf space at Walmart. These strategic moves align with ADIA's mission to revolutionize the supplement industry and promote health and well-being.
ADIA Nutrition (OTC Pink: ADIA) has announced a strategic partnership with Cement Factory Nutrition, a health and wellness company co-owned by former WWE wrestler Jeff Sciullo (known as Elias). This collaboration aims to diversify and enhance ADIA's product offerings in the nutrition and supplement industry.
The partnership involves key figures from Cement Factory Nutrition, including professional bodybuilder AJ Sims and CEO Tomislav Marjanovic. ADIA's investment will be in the form of Series C Preferred Shares, reflecting Cement Factory Nutrition's confidence in ADIA's growth potential. This move is expected to leverage the expertise and resources of both companies to create innovative nutritional solutions.
ADIA Nutrition Inc. (OTC Pink: ADIA) has secured a $500,000 line of credit from CEO Larry Powalisz to support its strategic growth plan. The funds will be used to establish a clinic specializing in Autologous Hematopoietic Stem Cell Transplantation (aHSCT) for Multiple Sclerosis (MS) patients and expand its supplement divisions. Powalisz, diagnosed with MS 3.5 years ago, underwent aHSCT treatment in Mexico and has been in remission for 2.5 years. The company aims to make this treatment more accessible and affordable in the US by working with insurance companies. This initiative aligns with ADIA Nutrition's mission to revolutionize healthcare through innovative treatments and provide premium, organic supplements.
ADIA Nutrition Inc. (OTC Pink: ADIA) has announced the acquisition of Biolete , a company specializing in protein coffee with mushrooms. This strategic move expands ADIA's portfolio in the functional beverage market. The acquisition includes Biolete's trademarks, inventory, customer base, and website. ADIA acquired 100% of Biolete through an equity offer of preferred shares regulated under Rule 144, which doesn't affect current outstanding shares.
Biolete's products combine collagen protein and mushrooms in coffee, offering energy-boosting benefits without negative side effects. The acquisition is expected to immediately contribute to ADIA's earnings and provide new growth opportunities. ADIA plans to integrate Biolete's operations and expand distribution channels to accelerate product adoption.
ADIA Nutrition Inc. (OTC Pink: ADIA) has announced a strategic restructuring, introducing two new divisions: Medical and Supplement. The Medical Division will focus on a clinic for Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis patients. The Supplement Division aims to acquire or invest in companies producing organic supplements using US manufacturing processes.
CEO Larry Powalisz stated that this restructuring reflects ADIA's commitment to innovation and meeting evolving consumer demands. The company believes these new divisions will drive growth and positively impact individuals' lives. ADIA Nutrition Inc. aims to reinforce its position as a trailblazer in the nutrition industry through this strategic move.